Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LeonaBio, Inc.LONA · Entity 1487 | Director | June 23, 2026 | June 24, 2026 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director · CHIEF EXECUTIVE OFFICER | September 08, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LeonaBio, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.35 · Expires 2036-06-22 | Direct | 28,000 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 28,000 · Balance 28,000 F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.
Vaxcyte, Inc.
Report date September 08, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 429,902 |
Reported balance
After 2026-09-08 transaction · row 1
1 source rowRow 1 · 2026-09-08 · Tax withholding · Disposed 17,056 · Balance 429,902 F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. |
| Common StockSEC Table I · non-derivative | IndirectBy Children's Trust | 133,215 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 133,215 F2: Shares are held directly by a trust for the benefit of the Reporting Person's son. |
| Common StockSEC Table I · non-derivative | IndirectBy Children's Trust | 133,215 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 133,215 F3: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
F2: Shares are held directly by a trust for the benefit of the Reporting Person's son.
F3: Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2024 Filed Mar 5, 2024 02:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 363 | $74.69 | $27,113.56 |
DisclosureSEC source: 0001415889-24-006472 · form4-03052024_020352.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 148,670 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F6 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $74.55 to $74.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F4 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 02:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 439 | $73.54 | $32,282.30 |
DisclosureSEC source: 0001415889-24-006472 · form4-03052024_020352.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 149,033 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.42 to $73.71. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F4 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 02:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 506 | $73.04 | $36,957.23 |
DisclosureSEC source: 0001415889-24-006472 · form4-03052024_020352.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 149,472 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.39 to $73.34. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F4 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 02:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 205,000 | $0.00 Strike: $73.82 | $0.00 |
DisclosureSEC source: 0001415889-24-006472 · form4-03052024_020352.xml · derivative · entry 9 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock · 205,000 shares Expires 2034-02-28 F11 · derivative.exercise_date: 1/48 of shares subject to the option vest on March 31, 2024, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 02:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006472 · form4-03052024_020352.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 420,814 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on August 31, 2024 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001415889-24-005476 · form4-02272024_090231.xml · derivative · entry 11 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,225 Underlying: Common Stock · 30,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 30,000 | $79.03 | $2,370,900.00 |
DisclosureSEC source: 0001415889-24-005476 · form4-02272024_090231.xml · nonDerivative · entry 7 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 375,814 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $79.03 to $79.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 30,000 | $1.79 | $53,700.00 |
DisclosureSEC source: 0001415889-24-005476 · form4-02272024_090231.xml · nonDerivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 405,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001415889-24-005476 · form4-02272024_090231.xml · derivative · entry 10 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,225 Underlying: Common Stock · 15,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 119 | $77.56 | $9,229.64 |
DisclosureSEC source: 0001415889-24-005476 · form4-02272024_090231.xml · nonDerivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 375,814 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,545 | $76.95 | $426,698.84 |
DisclosureSEC source: 0001415889-24-005476 · form4-02272024_090231.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 375,933 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $76.54 to $77.475. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 6,980 | $75.96 | $530,214.76 |
DisclosureSEC source: 0001415889-24-005476 · form4-02272024_090231.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 381,478 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $75.545 to $76.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,356 | $75.15 | $177,062.82 |
DisclosureSEC source: 0001415889-24-005476 · form4-02272024_090231.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 388,458 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $74.45 to $75.52. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 15,000 | $1.79 | $26,850.00 |
DisclosureSEC source: 0001415889-24-005476 · form4-02272024_090231.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 390,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 281 | $75.49 | $21,211.57 |
DisclosureSEC source: 0001415889-24-002611 · form4-02052024_100248.xml · nonDerivative · entry 8 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 149,978 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F11 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $75.23 to $75.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F8 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 238 | $74.56 | $17,745.76 |
DisclosureSEC source: 0001415889-24-002611 · form4-02052024_100248.xml · nonDerivative · entry 7 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 150,259 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F10 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $74.13 to $75.01. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F8 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 655 | $73.34 | $48,038.36 |
DisclosureSEC source: 0001415889-24-002611 · form4-02052024_100248.xml · nonDerivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 150,497 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F9 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.01 to $73.77. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F8 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 134 | $71.93 | $9,638.75 |
DisclosureSEC source: 0001415889-24-002611 · form4-02052024_100248.xml · nonDerivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 151,152 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F7 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $71.69 to $71.94. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F8 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 255 | $75.47 | $19,245.62 |
DisclosureSEC source: 0001415889-24-002611 · form4-02052024_100248.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 149,978 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F6 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $75.21 to $75.69. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 443 | $74.37 | $32,944.14 |
DisclosureSEC source: 0001415889-24-002611 · form4-02052024_100248.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 150,233 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $74.01 to $74.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 491 | $73.26 | $35,968.21 |
DisclosureSEC source: 0001415889-24-002611 · form4-02052024_100248.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 150,676 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.995 to $73.37. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 119 | $71.93 | $8,560.15 |
DisclosureSEC source: 0001415889-24-002611 · form4-02052024_100248.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 151,167 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $71.69 to $71.94. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 21:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001415889-24-002055 · form4-01312024_090110.xml · derivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,225 Underlying: Common Stock · 30,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 21:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 30,000 | $66.03 | $1,980,900.00 |
DisclosureSEC source: 0001415889-24-002055 · form4-01312024_090110.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 375,814 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 21:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 30,000 | $1.79 | $53,700.00 |
DisclosureSEC source: 0001415889-24-002055 · form4-01312024_090110.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 405,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 22:50 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001415889-24-001821 · form4-01252024_100131.xml · derivative · entry 9 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,225 Underlying: Common Stock · 12,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 22:50 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001415889-24-001821 · form4-01252024_100131.xml · derivative · entry 8 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 663 Underlying: Common Stock · 3,000 shares Expires 2025-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 22:50 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,039 | $64.78 | $132,086.42 |
DisclosureSEC source: 0001415889-24-001821 · form4-01252024_100131.xml · nonDerivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 375,814 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $64.70 to $64.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 22:50 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 10,023 | $63.95 | $640,970.85 |
DisclosureSEC source: 0001415889-24-001821 · form4-01252024_100131.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 377,853 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $63.66 to $64.625. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 22:50 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,938 | $63.22 | $185,725.67 |
DisclosureSEC source: 0001415889-24-001821 · form4-01252024_100131.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 387,876 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $62.625 to $63.61. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 22:50 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 12,000 | $1.79 | $21,480.00 |
DisclosureSEC source: 0001415889-24-001821 · form4-01252024_100131.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 390,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 22:50 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 3,000 | $0.04 | $120.00 |
DisclosureSEC source: 0001415889-24-001821 · form4-01252024_100131.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 378,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:24 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 643 | $64.24 | $41,304.39 |
DisclosureSEC source: 0001209191-24-000779 · doc4.xml · nonDerivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 151,286 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $64.13 to $64.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F7 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:24 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 568 | $63.68 | $36,171.38 |
DisclosureSEC source: 0001209191-24-000779 · doc4.xml · nonDerivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 151,929 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F8 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $63.13 to $64.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F7 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:24 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 97 | $62.91 | $6,102.37 |
DisclosureSEC source: 0001209191-24-000779 · doc4.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 152,497 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F6 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $62.01 to $62.94. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F7 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:24 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 587 | $64.33 | $37,763.47 |
DisclosureSEC source: 0001209191-24-000779 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 151,286 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $64.13 to $64.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:24 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 594 | $63.65 | $37,810.48 |
DisclosureSEC source: 0001209191-24-000779 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 151,873 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $63.01 to $64.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:24 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 127 | $62.93 | $7,992.11 |
DisclosureSEC source: 0001209191-24-000779 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 152,467 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $62.01 to $62.96. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| December 26, 2023 Filed Dec 27, 2023 21:35 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-059791 · doc4.xml · derivative · entry 8 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,663 Underlying: Common Stock · 10,000 shares Expires 2025-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| December 26, 2023 Filed Dec 27, 2023 21:35 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 7,550 | $62.08 | $468,681.35 |
DisclosureSEC source: 0001209191-23-059791 · doc4.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 375,814 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $61.96 to $62.17. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 26, 2023 Filed Dec 27, 2023 21:35 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 7,450 | $61.32 | $456,856.35 |
DisclosureSEC source: 0001209191-23-059791 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 383,364 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $60.885 to $61.76. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 26, 2023 Filed Dec 27, 2023 21:35 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 10,000 | $0.04 | $400.00 |
DisclosureSEC source: 0001209191-23-059791 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 390,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 21:35 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 9,900 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001209191-23-059791 · doc4.xml · derivative · entry 7 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 292,327 Underlying: Common Stock · 9,900 shares Expires 2028-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 21:35 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 9,900 | $2.03 | $20,097.00 |
DisclosureSEC source: 0001209191-23-059791 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 380,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 552 | $52.68 | $29,077.15 |
DisclosureSEC source: 0001209191-23-057399 · doc4.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 152,594 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F7 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $52.42 to $52.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 757 | $51.71 | $39,141.44 |
DisclosureSEC source: 0001209191-23-057399 · doc4.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 153,146 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $51.29 to $52.21. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 841 | $52.50 | $44,155.02 |
DisclosureSEC source: 0001209191-23-057399 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 152,594 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $52.21 to $52.90. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 468 | $51.43 | $24,068.77 |
DisclosureSEC source: 0001209191-23-057399 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 153,435 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $51.175 to $52.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| November 24, 2023 Filed Nov 28, 2023 21:50 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,779 | $49.46 | $186,921.81 |
DisclosureSEC source: 0001209191-23-056818 · doc4.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 370,914 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $49.35 to $49.89. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 24, 2023 Filed Nov 28, 2023 21:50 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 11,221 | $48.96 | $549,377.92 |
DisclosureSEC source: 0001209191-23-056818 · doc4.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 374,693 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $48.345 to $49.33. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.